Evidence map›Paper›PMID 40090763›Full record

ArticleJournal of cutaneous pathology2025

Primary Cutaneous Neoplasm With Rhabdomyosarcomatous Differentiation and a Melanoma-Like Mutational Landscape.

Maximillian A Weigelt, Shinoj Pattali, Josephine K Dermawan, Jennifer S Ko, Karen J Fritchie, Steven D Billings

Abstract readCase Reports
In one paragraph

Article in Journal of cutaneous pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Maximillian A WeigeltDepartment of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio, USA.ORCID https://orcid.org/0000-0001-9375-4466
Shinoj PattaliDepartment of Hematology and Oncology, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Josephine K DermawanDepartment of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
Jennifer S KoDepartment of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio, USA.ORCID https://orcid.org/0000-0003-0629-775X
Karen J FritchieDepartment of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
Steven D BillingsDepartment of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio, USA.ORCID https://orcid.org/0000-0002-2278-5908

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant melanoma (MM) is notorious for its wide range of morphologic variability. Rarely, MM may lose all melanocytic markers and adopt the morphologic and immunophenotypic characteristics of a different neoplasm in a process known as trans-differentiation (TMM). Distinguishing TMM from primary cutaneous neoplasms may be challenging and is often dependent on the identification of an adjacent conventional melanoma. In particularly difficult cases, molecular analysis may be helpful; TMMs are known to exhibit highly similar mutational landscapes to conventional melanomas (e.g., mutations in NF1, NRAS; variable BRAF V600E). Herein, we present an exceedingly rare case of likely TMM with rhabdomyosarcomatous differentiation in which high tumor mutational burden (TMB) was an important clue to the diagnosis. An 83-year-old woman presented with an 8.2 cm fungating mass on the upper arm. Biopsy revealed a sheet-like proliferation of mitotically active pleomorphic cells which were positive for myogenin/MyoD1 and negative for S100/SOX10. A diagnosis of epithelioid rhabdomyosarcoma was rendered. Subsequent axillary lymph node metastasis prompted whole exome sequencing, which revealed a molecular signature more indicative of MM, including: high TMB (19 mutations/Mb); ultraviolet mutational signature (i.e., preponderance of C>T base changes); TERT promoter mutation; and ARID2 mutation. After discussion at the interdisciplinary tumor board, a diagnosis of TMM was considered most likely, and the patient was initiated on pembrolizumab. Morphologic features more typical of MM than cutaneous sarcomas, such as tumor-infiltrating lymphocytes, junctional epidermal tumor nests, and satellitosis, may provide further clues to the accurate diagnosis of TMM, which has important prognostic and therapeutic implications for the patient.

Indexed as

MelanomaRhabdomyosarcomaSkin NeoplasmsAged, 80 and overBiomarkers, TumorCell DifferentiationCutaneous Malignant MelanomaDiagnosis, DifferentialFemaleHumansMutationBiomarkers, TumormelanomamolecularPD‐1rhabdomyosarcomatrans‐differentiatedwhole exome sequencing

Identifiers

PMID40090763
PMCPMC12061625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.